<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471065</url>
  </required_header>
  <id_info>
    <org_study_id>2018-03</org_study_id>
    <nct_id>NCT03471065</nct_id>
  </id_info>
  <brief_title>The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic Severe Aortic Stenosis</brief_title>
  <official_title>A Prospective, Single-arm, Multicenter Study of the SAPIEN 3 Ultra Delivery System Used With the SAPIEN 3 Ultra THV and SAPIEN 3 THV in Intermediate Risk Patients With Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Single-arm, Study of the Edwards Lifesciences SAPIEN 3 Ultra Delivery System
      used with the SAPIEN 3 Ultra THV and SAPIEN 3 THV in Intermediate Risk Patients with Severe,
      Calcific, Aortic Stenosis Requiring Aortic Valve Replacement
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The procedural safety and procedural performance of the SAPIEN 3 Ultra Transcatheter Heart
      Valve (THV) System in subjects with severe, calcific aortic stenosis who are at intermediate
      operative risk for standard aortic valve replacement (AVR) will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural success defined as freedom from mortality</measure>
    <time_frame>Day 0</time_frame>
    <description>End of procedure is defined as day 0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number/percentage of patients who have a major vascular complication as per VARC II definition</measure>
    <time_frame>3 days</time_frame>
    <description>Discharge</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be implanted with the SAPIEN 3 Ultra THV using the SAPIEN 3 Ultra Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVR</intervention_name>
    <description>Implantation of the SAPIEN 3 Ultra THV using the SAPIEN 3 Ultra Delivery System</description>
    <arm_group_label>SAPIEN 3 Ultra Delivery System with the SAPIEN 3 Ultra THV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        study:

          1. Severe, calcific aortic stenosis meeting the following transthoracic echocardiogram
             (TTE) criteria: Aortic valve area (AVA) ≤ 1.0 cm2 OR AVA index ≤ 0.6 cm2/m2 and jet
             velocity ≥ 4.0 m/s OR mean gradient ≥ 40 mmHg

          2. New York Heart Association (NYHA) functional class ≥ II

          3. Judged by the Heart Team to be at intermediate risk for open surgical therapy

          4. The subject has been informed of the nature of the study, agrees to its provisions and
             has provided written informed consent as approved by the Institutional Review
             Board/Ethics Committee of the respective clinical site.

        Exclusion Criteria:

          1. Aortic valve is unicuspid, bicuspid or non-calcified

          2. Pre-existing mechanical or bioprosthetic valve in any position.

          3. Severe aortic regurgitation (&gt; 3+)

          4. Severe mitral regurgitation (&gt; 3+) or ≥ moderate stenosis

          5. Evidence of an acute myocardial infarction ≤ 30 days before the valve implant
             procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tenley Koepnick</last_name>
    <phone>949-250-6504</phone>
    <email>Tenley_Koepnick@edwards.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter</keyword>
  <keyword>Transcatheter Valve Replacement</keyword>
  <keyword>SAPIEN 3 Ultra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

